A Phase IIIb, Open Label, Multi Center Extension Study of V72_28 to Assess Antibody Persistence, and the Safety and Tolerability of a Booster Dose After the Completion of the Vaccination Course in Study V72_28
Overview
- Phase
- Phase 3
- Intervention
- Not specified
- Conditions
- Meningoccocal Disease
- Sponsor
- Novartis Vaccines
- Enrollment
- 851
- Locations
- 17
- Primary Endpoint
- The hSBA Geometric Mean Titers (GMTs) Against N.Meningitidis Serogroup B Strains
- Status
- Completed
- Last Updated
- 4 years ago
Overview
Brief Summary
The aim of this extension study is to explore the antibody persistence 24 to 36 months after the last dose of vaccine, in infants that received a two or three dose primary series plus a booster dose at 11 months of age, of the Novartis meningococcal B vaccine (Bexsero®) in groups I to III of the parent V72_28 study.
This study will also explore the antibody persistence 24 to 36 months after two catch-up doses of the Novartis meningococcal B vaccine (Bexsero®) administered in children (2 to 10 years old) in group IV of the parent V72_28 study.
Investigators
Eligibility Criteria
Inclusion Criteria
- •For naïve subjects newly enrolled:
- •Healthy infants and children according to the following age groups:
- •Healthy subjects from 35 to 47 months of age, (only applicable to group K) (The age window is defined as the first day the subject turns 35 months of age up to the day before the subject turns 48 months of age),
- •Healthy subjects 4 to 7 years of age (only applicable to group L) (The age window is defined as the first day the subject turns 4 years of age up to the day before the subject turns 8 years of age).
- •Healthy subjects 8 to 12 years of age (only applicable to group M) (The age window is defined as the first day the subject turns 8 years of age up to the day before the subject turns 13 years of age).
- •for whom a parent/legal guardian has given written informed consent after the nature of the study has been explained;
- •for whom a parent/legal guardian confirmed availability for the visit scheduled in the study;
- •in good health as determined by medical history, physical examination, clinical judgment of the investigator.
- •For Subjects who participated in the V72_28 study (Follow-on Subjects):
- •for whom a parent/legal guardian has given written informed consent after the nature of the study has been explained;
Exclusion Criteria
- •For naïve subjects newly enrolled:
- •History of any serogroup B meningococcal vaccine administration;
- •Previous known or suspected disease caused by N. meningitidis;
- •Household contact with and/or intimate exposure to an individual with laboratory confirmed N. meningitidis infection or colonization;
- •History of severe allergic reaction after previous vaccinations or hypersensitivity to any component of the vaccine;
- •Pregnancy or nursing (breastfeeding) mothers;
- •Females of childbearing age who have not used or do not plan to use acceptable birth control measures, for the duration of the study. Oral, injected or implanted hormonal contraceptive, barrier methods (condom or diaphragm with spermicide), intrauterine device, surgical sterilization, transdermal delivery, congenital sterility or sexual abstinence are considered acceptable forms of birth control. If sexually active the subject must have been using one of the accepted birth control methods at least two months prior to study entry;
- •Known or suspected autoimmune disease or impairment/alteration of the immune system resulting from (for example):
- •Receipt of any chronic immunosuppressive therapy
- •Receipt of any chronic immunostimulants
Outcomes
Primary Outcomes
The hSBA Geometric Mean Titers (GMTs) Against N.Meningitidis Serogroup B Strains
Time Frame: 24-36 months after booster dose in the parent study; baseline for vaccine-naïve subjects
The hSBA antibody titers in subjects, 24 to 36 months after completion of Bexsero® vaccination course according to different schedules in the parent study, are presented in terms of vaccine-group-specific GMTs, alongside with the corresponding antibody responses in age-matched vaccine-naïve subjects at baseline.
The Geometric Mean Ratio (GMR) of hSBA GMTs Against N. Meningitidis Serogroup B, 24 to 36 Months Versus Visit 1 in the Parent Study.
Time Frame: At Day 1 in this study over visit 1 in the vaccination course in the parent study
The within-subjects GMR of GMTs at 24 to 36 months versus visit 1 in the vaccination course according to different schedules vaccination in the parent study are reported.
Percentage of Subjects With hSBA Titers ≥ 8 Against N.Meningitidis Serogroup B Strains
Time Frame: At 24-36 months after booster dose in the parent study: baseline for vaccine-naïve subjects
The antibody persistence in subjects, 24 to 36 months after completion of Bexsero® vaccination course in the parent study according to different schedules is presented in terms of the percentage of subjects in each vaccine group with hSBA titers ≥ 8, alongside with the corresponding antibody responses in age matched vaccine naïve subjects at baseline.
The Geometric Mean Ratio (GMR) of hSBA GMTs Against N. Meningitidis Serogroup B, 24 to 36 Months Versus 1 Month After Completion of Bexsero® Vaccination Course According to Different Schedules in the Parent Study.
Time Frame: At Day 1 in this study over one month after the completion of the vaccination course in the parent study
The within-subjects GMR of GMTs at 24 to 36 months versus 1 month after completion of Bexsero® vaccination course according to different schedules vaccination in parent study are reported.
Percentage of Subjects With Human Serum Bactericidal Activity Titers (hSBA) ≥ 4 or ≥ 5 Against Neisseria Meningitidis (N. Meningitidis) Serogroup B Strains
Time Frame: 24-36 months after booster dose in the parent study; baseline for vaccine-naïve subjects
The antibody persistence in subjects, 24 to 36 months after completion of Bexsero® vaccination course in the parent study according to different schedules, is presented in terms of the percentage of subjects in each vaccine group, with hSBA titers ≥ 4 for what concerns the H44/76, 5/99 and NZ98/254 strains, and hSBA titers ≥ 5 for M10713 strain, alongside with the corresponding antibody responses in age-matched vaccine naïve subjects at baseline. The functional bactericidal antibodies directed against serogroup B meningococcal were assessed by the Serum Bactericidal Assay (SBA) using human serum as the source of exogenous complement (hSBA).
Secondary Outcomes
- Percentage of Subjects With Four-fold Rise in hSBA Titers, After Receiving Two Catch up Doses of Bexsero® Vaccination.(One month post second vaccination (Day 61))
- Percentage of Subjects With hSBA Titers ≥ 8 Against N.Meningitidis serogroupB, After Receiving Bexsero® Booster Vaccination in This Study.(At 24-36 months (Visit 1) and one month after booster vaccination (Day 31))
- Percentage of Subjects With Four-fold Rise in hSBA Titers, After Receiving Bexsero® Vaccination in This Study.(One month after booster vaccination (day 31)/24-36 months (Visit 1))
- The GMTs in Subjects Who Received Two Catch up Doses of Bexsero® Vaccination.(At Baseline and One month post second vaccination (Day 61))
- The GMTs Against N.Meningitidis Serogroup B, One Month After Receiving Bexsero® Booster Vaccination in the Present Study.(At Visit 1 and one month post booster vaccination (Day 31))
- The Geometric Mean Ratio (GMR) of hSBA Titers, One Month After Receiving Bexsero® Booster Vaccination in the Present Study.(Visit 2 (day 31 in extension study) versus post primary vaccination visit in parent study)
- Percentage of Subjects With hSBA Titers ≥4 or ≥ 5 Against N.Meningitidis Serogroup B, After Receiving Bexsero® Booster Vaccination in This Study.(At 24-36 months (Visit 1) and one month after booster vaccination (Day 31))
- Percentage of Subjects With Four-fold Rise in hSBA Titers, One Month After Receiving Bexsero® Vaccination in This Study(From post primary visit in the parent study to visit 2 in this extension study)
- Percentage of Subjects With hSBA Titers ≥ 4 or ≥ 5, After Receiving Two Catch up Doses of Bexsero® Vaccination(At Baseline and One month post second vaccination (Day 61))
- Percentage of Subjects With hSBA Titers ≥ 8 , After Receiving Two Catch up Doses of Bexsero® Vaccination.(At Baseline and One month post second vaccination (Day 61))
- The GMRs of hSBA Titers After Two Catch up Doses of Bexsero® Vaccination Versus hSBA Titers at Baseline.(At one month after receiving second vaccination (Day 61) versus baseline (Day 1))
- Number of Subjects Reporting Unsolicited Serious Adverse Events (SAEs), Medically Attended AEs and AEs Leading to Withdrawal for Entire Study Period.(Throughout the entire study period (up to 2 months))
- Percentage of Subjects With Four-fold Rise in hSBA Titers, One Month After Receiving Bexsero® Vaccination in This Study.(From pre primary visit in the parent study (Visit 1) to visit 2 in this extension study)
- Number of Subjects (35 Months to 7 Years of Age) Reporting Solicited Local and Systemic Adverse Events After Receiving Bexsero® Booster Vaccine.(From day 1 (6 hr) through day 7 after vaccination)
- Number of Subjects Reporting Unsolicited Adverse Events After Receiving Bexsero® Vaccination.(From day 1 through day 7 after any vaccination)
- Number of Newly Recruited Subjects (Aged 35 Months to 7 Years) Reporting Solicited Local and Systemic Adverse Events After Receiving Catch-up Doses of Bexsero® Vaccine.(From day 1 (6 hr) through day 7 after vaccination)
- Number of Subjects (8 to 12 Years of Age) Reporting Solicited Local and Systemic Adverse Events After Receiving Bexsero® Booster Vaccine.(From day 1 (6 hr) through day 7 after vaccination)
- Number of Newly Recruited naïve Subjects (Aged 8 to 12 Years of Age) Solicited Local and Systemic Adverse Events After Receiving Bexsero® Vaccine.(From day 1(6 hr) through day 7 after vaccination)